Satellos Bioscience (TSX:MSCL) Common Stock : C$61.92 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Common Stock?

Satellos Bioscience's quarterly common stock stayed the same from Sep. 2023 (C$61.92 Mil) to Dec. 2023 (C$61.92 Mil) and stayed the same from Dec. 2023 (C$61.92 Mil) to Mar. 2024 (C$61.92 Mil).

Satellos Bioscience's annual common stock increased from Dec. 2021 (C$28.32 Mil) to Dec. 2022 (C$30.21 Mil) and increased from Dec. 2022 (C$30.21 Mil) to Dec. 2023 (C$61.92 Mil).

Satellos Bioscience Common Stock Historical Data

The historical data trend for Satellos Bioscience's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Common Stock Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

4.36

28.32

30.21

61.92

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial										30.44	61.92	61.92	61.92	61.92

Satellos Bioscience Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines